Fycompa in Catamenial Epilepsy

Catamenial Epilepsy Clinical Trial

Official title:
Pilot Study of Add-On Fycompa (Perampanel)Treatment for Catamenial Epilepsy

Status Recruiting

Clinical Trial Summary

The purpose of the proposed investigation is to carry out a pilot study of add-on perampanel (Fycompa) in women with perimenstural (C1) catamenial epilepsy. Perampanel, a noncompetitive AMPA receptor antagonist, is uniquely positioned to decrease progesterone receptor mediated excitotoxicity. This mechanism of action would allow a novel use of perampanel as an effective treatment of C1 catamenial epilepsy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05201703
Study type	Interventional
Source	University of Florida
Contact
Status	Recruiting
Phase	Phase 4
Start date	March 9, 2022
Completion date	December 15, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02426047` - Medium Chain Triglycerides as an Adjunct to the Modified Atkins Diet for Women With Catamenial Epilepsy	N/A
Withdrawn	`NCT00559169` - Verapamil and Catamenial Epilepsy	N/A
Completed	`NCT00465517` - A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures	Phase 2